The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies
- PMID: 1720502
- DOI: 10.1016/0161-5890(91)90005-5
The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies
Abstract
Rabbits were immunized with immunotype L3,7,9 phosphoethanolamine (PEA) group containing oligosaccharide-tetanus toxoid conjugates both with and without the addition of the adjuvant Quil A. The epitope specificity of the antibodies present in these antisera was analysed in an immunotype L2 and L3,7,9 specific inhibition ELISA using the homologous and heterologous lipopolysaccharide, oligosaccharide and partial dephosphorylated oligosaccharide as inhibitors. Two groups of antisera could be identified. In one group of antisera, at least two antibody populations are present, namely directed against the PEA group containing determinants on immunotype L3,7,9 lipopolysaccharide and against immunotype L2 specific epitopes in which no PEA group is present. In the second group of antisera, one but probably more antibody populations are detected with a similar specificity towards the conserved epitopes of both immunotypes. In general, immunization with the conjugates only resulted in the induction of antibodies against the PEA group containing epitopes on the L3,7,9 lipopolysaccharide (80%). Antibodies directed against the conserved epitopes of both immunotypes are mainly evoked with the conjugates in combination with the adjuvant Quil A (80%). Although these results suggest that the epitope specificity of the antibodies induced depends on the use of Quil A, the influence of genetic factors cannot be excluded. At the moment it is not known whether the differences in epitope specificities are reflected in biological function of these antibodies. However, the induction of antibodies with clearly different epitope specificities after immunization of different rabbits with the same antigen stresses the importance of this kind of analysis when developing a vaccine based on oligosaccharide-protein conjugates.
Similar articles
-
Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.Infect Immun. 1991 Mar;59(3):843-51. doi: 10.1128/iai.59.3.843-851.1991. Infect Immun. 1991. PMID: 1900063 Free PMC article.
-
Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.Infect Immun. 1991 Oct;59(10):3566-73. doi: 10.1128/iai.59.10.3566-3573.1991. Infect Immun. 1991. PMID: 1910006 Free PMC article.
-
Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.Infect Immun. 1993 Jan;61(1):187-96. doi: 10.1128/iai.61.1.187-196.1993. Infect Immun. 1993. PMID: 8418041 Free PMC article.
-
The blood group Ii system: a carbohydrate antigen system defined by naturally monoclonal or oligoclonal autoantibodies of man.Immunol Commun. 1981;10(2):127-56. doi: 10.3109/08820138109050693. Immunol Commun. 1981. PMID: 6169630 Review.
-
Techniques for localizing contractile proteins with fluorescent antibodies.Curr Top Dev Biol. 1980;14(Pt 2):271-96. doi: 10.1016/s0070-2153(08)60198-2. Curr Top Dev Biol. 1980. PMID: 6161755 Review. No abstract available.
Cited by
-
Comparative analysis of two meningococcal immunotyping monoclonal antibodies by resonant mirror biosensor and antibody gene sequencing.Clin Diagn Lab Immunol. 1999 Nov;6(6):838-43. doi: 10.1128/CDLI.6.6.838-843.1999. Clin Diagn Lab Immunol. 1999. PMID: 10548573 Free PMC article.
-
Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.Infect Immun. 2001 Feb;69(2):787-93. doi: 10.1128/IAI.69.2.787-793.2001. Infect Immun. 2001. PMID: 11159969 Free PMC article.
-
Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.Clin Diagn Lab Immunol. 1994 Nov;1(6):729-36. doi: 10.1128/cdli.1.6.729-736.1994. Clin Diagn Lab Immunol. 1994. PMID: 8556528 Free PMC article.
-
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.Microbiol Rev. 1993 Mar;57(1):34-49. doi: 10.1128/mr.57.1.34-49.1993. Microbiol Rev. 1993. PMID: 8464406 Free PMC article. Review.
-
Current status of meningococcal group B vaccine candidates: capsular or noncapsular?Clin Microbiol Rev. 1994 Oct;7(4):559-75. doi: 10.1128/CMR.7.4.559. Clin Microbiol Rev. 1994. PMID: 7834605 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources